Christopher E. Brightling

2 months ago | publications.ersnet.org | Neil Martin |Michael E. Wechsler |Christopher E. Brightling

Reply to S. Mailhot-Larouche and co-workers:We thank S. Mailhot-Larouche and co-workers for their interest in our recent publication on clinical response and clinical remission with tezepelumab treatment, reporting results over 2 years from patients with severe, uncontrolled asthma enrolled in the NAVIGATOR and DESTINATION clinical trials [1].

Mar 7, 2024 | erj.ersjournals.com | Richard Russell |Christopher E. Brightling |Ian D Pavord

FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Oct 16, 2023 | thelancet.com | S Byrne |Christopher E. Brightling |Rachael Evans |Amisha Singapuri

Key questions discussed at the PHOSP-COVID Scientific SummitThe PHOSP-COVID Scientific Summit included a review of progress and a discussion focused on four key questions pertaining to future research that were identified in advance of the summit. Question 1: How should we approach future pandemic research for long-term sequelae?

Mar 30, 2023 | erj.ersjournals.com | Jonathan Corren |Christopher E. Brightling |Michael E. Wechsler |Andrew Menzies-Gow

Thank you for your interest in spreading the word on European Respiratory Society . NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas.